Results 21 to 30 of about 11,837 (160)

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Correction to "Persistent <i>Burkholderia cepacia</i> Bacteremia in Reconstructive Surgery: Resistance to Ceftazidime/Avibactam and Co-Trimoxazole With Risk of Infective Endocarditis-A Case Report". [PDF]

Clin Case Rep
Clinical Case Reports, Volume 14, Issue 2, February 2026.
europepmc   +2 more sources

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales

Antibiotics, 2020
Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited.
Antonio Vena, Daniele Roberto Giacobbe, Nadia Castaldo, Annamaria Cattelan, Cristina Mussini, Roberto Luzzati, Francesco Giuseppe De Rosa, Filippo Del Puente, Claudio Maria Mastroianni, Antonio Cascio, Sergio Carbonara, Alessandro Capone, Silvia Boni, Chiara Sepulcri, Marianna Meschiari, Francesca Raumer, Alessandra Oliva, Silvia Corcione, Matteo Bassetti, for the Ceftabuse Study Group   +19 more
doaj   +1 more source

Ceftazidime-Avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope

Annals of Clinical Microbiology and Antimicrobials, 2023
Background Carbapenemase-producing Enterobacterales (CPE) show rapid global dissemination and pose a significant therapeutic challenge. This study aimed to characterize carbapenemase-producing Klebsiella spp. and Escherichia coli ( E.
Rawan Taha, O. Kader, S. Shawky, Shahinda Rezk   +3 more
semanticscholar   +1 more source

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing Klebsiella pneumoniae Clinical Isolates

Antibiotics, 2023
The novel β-lactam/β-lactamase inhibitor combinations (βL-βLICs) are one of the last-line resources available against multidrug-resistant (MDR) Gram-negative bacteria.
Marta Palombo, Benedetta Secci, Federica Bovo, Milo Gatti, Simone Ambretti, Paolo Gaibani   +5 more
doaj   +1 more source

IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES

İstanbul Tıp Fakültesi Dergisi, 2022
Objective: Infections caused by multi drug-resistant Gram-negative bacilli are increasingly reported worldwide. Ceftazidime-avibactam is a novel antibiotic combination that presents good activity against carbapenem-resistant Enterobacterales members and ...
Tuğrul Hoşbul, Canset Nur Aydoğan, Sinem Kaya, Orhan Bedir, Hande Özcan, Ramazan Gümral   +5 more
doaj   +1 more source

Persistent <i>Burkholderia cepacia</i> Bacteremia in Reconstructive Surgery: Resistance to Ceftazidime/Avibactam and Co-Trimoxazole With Risk of Infective Endocarditis-A Case Report. [PDF]

Clin Case Rep
ABSTRACT Persistent Burkholderia cepacia bacteremia in soft tissue infections creates diagnostic and therapeutic challenges due to its resistance profile and potential for endovascular involvement. Early culture‐guided therapy, multidisciplinary coordination, and vigilance for complications, such as infective endocarditis, are essential for achieving ...
Elendu C, Amaechi DC, Elendu TC, Amaechi EC, Elendu ID, Ikedilo AS.   +5 more
europepmc   +2 more sources

An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance

Open Forum Infectious Diseases, 2023
Background Cefiderocol and ceftazidime-avibactam plus aztreonam (CZA-ATM) are preferred treatment regimens for New Delhi metallo-β-lactamase (NDM)-producing infections.
P. Simner, Y. Bergman, Rick Conzemius, E. Jacobs, Tsigereda Tekle, S. Beisken, P. Tamma   +6 more
semanticscholar   +1 more source

Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study.

Journal of Infection and Public Health, 2023
OBJECTIVES Limited data on clinical and microbiological efficacy, patient mortality, and other associated factors are available for ceftazidime/avibactam (CAZ/AVI)-based regimens for carbapenem-resistant Gram-negative bacteria (CR-GNB).
Haiwen Zhuang, Ying Chen, Qin Hu, Wen Long, Xiao-li Wu, Qin Wang, Tian T Xu, Q. Qu, Yi-Ping Liu, Yi Xiao, J. Qu   +10 more
semanticscholar   +1 more source

Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test

Journal of Clinical Microbiology, 2023
Due to limited therapeutic options, there is a clinical need to assess the in vitro activity of the combination of aztreonam (ATM) and ceftazidime-avibactam (CZA) to guide the therapeutic management of multidrug-resistant (MDR) Gram-negative organism ...
Harley T Harris, L. Tao, E. Jacobs, Y. Bergman, Ayomikun Adebayo, T. Tekle, Shawna Lewis, Ashley Dahlquist, Taylor C. Abbey, E. Wenzler, R. Humphries, P. Simner   +11 more
semanticscholar   +1 more source